DoxyPEP: The Morning-After Antibiotic for STIs, and What the WHO Actually Endorsed

For years, prevention of sexually transmitted infections meant condoms, testing and treatment after the fact. Then trials showed that a single dose of an old, cheap antibiotic taken shortly after sex could sharply cut the odds of catching syphilis or chlamydia. People started doing it informally long before any official body said a word. In 2026 the World Health Organization became the last major authority to catch up, issuing its first recommendation on the approach. This guide explains what doxyPEP actually does, who the evidence supports, and the honest catch that comes with taking an antibiotic to prevent an infection you do not yet have.

In short

• DoxyPEP means taking a single 200 mg dose of doxycycline within 72 hours after sex to lower the chance of catching a bacterial STI. The sooner after sex, the better.
• The evidence is strongest for syphilis and chlamydia, cut by more than 70 percent in the main trials. The effect on gonorrhoea is weaker and patchier, because resistance is already common.
• Official bodies recommend it for a specific group: mainly men who have sex with men and transgender women who have had a bacterial STI in the past year. The trials in cisgender women have so far been less convincing.
• The trade-off is antibiotic resistance. Regular doxycycline use can push bacteria, including bugs unrelated to STIs, toward resistance, which is why nobody recommends it for everyone.
• It does nothing against HIV or viral STIs such as herpes and HPV, and it is not a substitute for condoms, testing or vaccination.

What is doxyPEP and how do you take it?

DoxyPEP is a single 200 mg dose of the antibiotic doxycycline, taken as soon as possible and no later than 72 hours after condomless sex, to reduce the risk of certain bacterial STIs. The "PEP" stands for post-exposure prophylaxis, borrowing the term from HIV prevention: you take the medicine after a possible exposure rather than every day.

The dose is not taken with every act of sex in a marathon session; it is one 200 mg dose per encounter window, capped in practice so that people are not taking it daily. Guidance from bodies such as the US Centers for Disease Control and Prevention frames it as a prescription for self-administration: a person keeps a supply and uses a dose after sex that carried a real chance of exposure. Taken sooner works better, because the antibiotic is trying to stop an infection from establishing itself.

How well does it actually work?

Very well for syphilis and chlamydia, and only modestly for gonorrhoea. Across three large randomised trials, a 200 mg dose within 72 hours cut syphilis and chlamydia infections by more than 70 percent. That is a large, real effect, and it is the reason the approach moved from forums into formal guidance.

Gonorrhoea is the honest weak spot. Doxycycline reduced it by roughly half in some settings and barely at all in others, because Neisseria gonorrhoeae has been developing resistance to tetracycline antibiotics for decades. So the protection is uneven: strong against two infections, unreliable against a third, and absent against the viral ones. Anyone using doxyPEP as blanket cover is overestimating what it does.

Who is it recommended for, and who is left out?

The formal recommendations target people at genuinely high risk: mostly men who have sex with men and transgender women with a recent bacterial STI. That is where the trials showed clear benefit, and where the numbers make the resistance trade-off worth it. The WHO's 2026 recommendation and earlier guidance from the CDC and European CDC all draw that boundary deliberately.

Cisgender women are the notable gap. A major trial in women did not show the same protection, possibly because of how doxycycline reaches the cervix and how the infections present, so guidance stops short of a blanket recommendation there. This is not a moral judgement about who "deserves" prevention; it is the evidence being honest about where it is and is not solid. Meanwhile, real-world surveillance shows people were already using doxycycline informally well ahead of the official word, which is exactly why authorities felt pressure to publish clear guidance rather than leave a vacuum.

What is the catch? The resistance trade-off, honestly

Every dose of an antibiotic nudges bacteria toward resistance, and doxyPEP means a lot of doses across a lot of people. The concern is not only that gonorrhoea gets harder to prevent. It is that regular doxycycline exposure also selects for resistance in bystander bacteria, the ordinary bugs living on skin and in the gut, some of which cause other infections entirely. Doxycycline is a workhorse antibiotic for acne, chest infections, tick-borne illness and more, so protecting its usefulness matters beyond STIs.

This is the whole reason the recommendation is targeted rather than universal. Given to a high-risk group with frequent infections, the benefit is large enough to justify the resistance cost. Handed out to everyone "just in case," the maths flips: modest personal benefit, shared long-term harm. That balance, not squeamishness, is why officials draw a tight circle around who should use it.

What doxyPEP does not do

It does not protect against HIV or any viral STI, and it is not a reason to drop the other tools. Herpes, HPV, hepatitis and HIV are untouched by doxycycline. For HIV specifically, the relevant prevention is a different medicine taken as PrEP or as HIV PEP, not this. DoxyPEP also does not cancel out the value of condoms, the HPV and hepatitis B vaccines, or regular testing, which is how gonorrhoea and anything doxyPEP misses actually gets caught and treated. It is one useful layer, not a full coat.

When to see a doctor

Talk to a clinician before starting doxyPEP rather than sourcing it blind: the right candidates, the dosing limits and the testing schedule that should go with it are all worth getting right. See someone promptly if you have symptoms of an STI such as discharge, sores, pain on passing urine or an unexplained rash, because doxyPEP lowers risk but does not treat an infection you already have. And if you use it regularly, keep up routine STI screening, including for gonorrhoea, so anything it misses is found early.

This article is educational and does not replace advice from a doctor or pharmacist who knows your health history.